Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR), which makes a wearable device for treating cancer. The average investor might see NovoCure as yet another struggling cancer therapy company.

But smart investors see its less-appreciated advantages -- and also its lesser-known warts. So without further ado, let's dive in and think about three of the nuances that smart investors can see about this business.

The biggest thing that smart investors know about NovoCure is that it's pretty much the only business making wearable anti-cancer devices that deliver tumor-treating electromagnetic fields to patients to slow down the rate of tumor growth in aggressive cancers.

Continue reading

Source Fool.com